Articles from Curve Biosciences

Curve Biosciences (“Curve”), the Whole-Body Intelligence™ company, today announced clinical results for performance of its Whole-Body Blood Test™ in monitoring high-risk liver disease patients for very early-stage hepatocellular carcinoma (HCC), the most common form of liver cancer. This blood test, powered by Curve’s Whole-Body Intelligence AI models, showed 77.8% sensitivity for very early-stage HCC (<2 cm lesions) while maintaining 81.5% specificity.

Curve Biosciences, the Whole-Body Intelligence™ company, today announced its Scientific Advisory Board (SAB), bringing together internationally recognized leaders in AI, genomics, and translational medicine.

Curve Biosciences today announced computational and clinical advancements from Whole-Body Intelligence, AI that reveals organ-specific biology in the blood using the company’s Whole-Body Atlas.

Curve Biosciences, the Whole-Body Intelligence™ company, today announced the appointment of Amit Singal, M.D., as Chief Medical Officer. A nationally recognized leader in clinical management of liver diseases like cirrhosis, hepatocellular carcinoma, and MASH, Dr. Singal brings deep clinical expertise, translational research leadership, and decades of experience advancing improved outcomes for patients with liver cirrhosis such as the earlier detection of liver cancer.

Curve Biosciences, the Whole-Body Intelligence™ company, today announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others.

Curve Biosciences (“Curve”), an early-stage company bringing precision to chronic disease care, today announced the addition of Nathan Hunkapiller, PhD, as chief scientific officer (CSO) and Chuba Oyolu, PhD, as chief technology officer (CTO). Hunkapiller leads Curve’s research and development, and Oyolu oversees technology development and software.